Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk
Stephen J. Nicholls(Australian Centre for Heart Health), Steven E. Nissen(Cleveland Clinic), Philip J. Barter(The Heart Research Institute), Martin Rensfeldt(AstraZeneca (Sweden)), Wolfgang Köenig(German Centre for Cardiovascular Research), Anders Himmelmänn(AstraZeneca (Sweden)), Christie M. Ballantyne(Baylor College of Medicine), Larrye E. Loss(AstraZeneca (United States)), Venu Menon(Cleveland Clinic), Dariush Mozaffarian(Tufts University), A. Michael Lincoff(Cleveland Clinic), John J.P. Kastelein(QRx Pharma (United States)), Torbjörn Lundström(AstraZeneca (Sweden)), Paul M. Ridker(Herlev Hospital), Rahul Agrawal(AstraZeneca (Sweden)), Michael H. Davidson(Kiadis Pharma (Netherlands)), Michelle Garcia(Center for Clinical Research (United States)), Dianna Bash(Center for Clinical Research (United States)), Brian G. Katona(AstraZeneca (United States)), Kathy Wolski(Cleveland Clinic), Darren K. McGuire(Parkland Health & Hospital System), Kausik K. Ray(Imperial College London)
Cited by 981
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction
|Circulation|2010|4.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k